Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial.

Cancers (Basel) · 2020 · PMC7761692 · PMID 33287189

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significancep = 0.09so close (0.05 < p ≤ 0.1)

Moreover, a similar pattern was observed in PB, with a lower expression of PD1 in CD8 + effector memory T cells, although differences did not reach statistical significance (MFI 548 vs. 761, p = 0.09) ( Figure 3 B).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.